Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Teva and Baxter to appeal $500 million US hepatitis propofol vial reuse award

This article was originally published in Scrip

Executive Summary

A unit of Teva Pharmaceutical Industries and Baxter Healthcare plan to appeal a combined $500 million punitive damages award of a Las Vegas jury, which found that vials of the anaesthetic propofol were not packaged with adequate warnings about improper use, specifically the dangers of reusing single-use vials among multiple patients. The case was the first to go to trial after an outbreak of hepatitis C several years ago in Southern Nevada, and hundreds of other lawsuits remain.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts